SCD, primarily affecting African and Hispanic Americans, involves a mutation in hemoglobin that leads to red blood cells developing a sickle shape. This mutation causes severe pain, organ damage, and potentially life-threatening complications.
Casgevy is designed for patients with recurrent vaso-occlusive crises (VOCs), which employs CRISPR/Cas9 to edit patients’ hematopoietic stem cells. These modified cells, once reinfused into the patient, increase fetal hemoglobin production, reducing red blood cell sickling. Lyfgenia, intended for patients with a history of vaso-occlusive events (VOEs), uses a lentiviral vector to modify stem cells to produce HbAT87Q, a therapeutic hemoglobin that lowers the sickling risk through cell-based gene therapy. Both treatments involve collecting and modifying the patient’s own blood stem cells, followed by a one-time infusion after high-dose chemotherapy (myeloablative conditioning).
Clinical trials demonstrated Casgevy’s efficacy, with over 93% of patients achieving freedom from severe VOCs. Lyfgenia showed 88% of patients had complete resolution of VOEs. Common side effects for both include low blood cell counts and mouth sores. Lyfgenia carries a black box warning for the risk of blood cancer.
These therapies, which received Priority Review and other FDA designations, are developed by Vertex Pharmaceuticals Inc. (Casgevy) and Bluebird Bio Inc. (Lyfgenia). The FDA’s approval highlights its commitment to advancing treatments for severe health conditions.
https://www.genengnews.com/topics/genome-editing/fda-approves-casgevy-the-first-crispr-therapy-for-sickle-cell-disease/
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Sangamo Therapeutics Secures Accelerated Approval Pathway for Gene Therapy in Fabry Disease
Sangamo Therapeutics has announced a major advancement in its gene therapy program for Fabry disease, as the U.S. FDA has provided a clear pathway for Accelerated Approval. This decision could potentially speed up approval timelines by three years, with a Biologics...
[2024/10/18] Gene and Cell Therapy- weekly digest from PackGene
FeaturedNewsArticlesPackGene's NewsletterReceive the latest news and insights to your inbox.About PackGenePackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span...
GSK sues Moderna over mRNA vaccine patents, seeks ‘reasonable royalty’
GSK on Tuesday unveiled a lawsuit filed against Moderna in Delaware federal court, alleging that its patented inventions provide the “foundation” for Moderna’s mRNA vaccine portfolio. GSK said it’s looking to recover “a reasonable royalty” for Moderna’s tens of...
Gene Therapy Automatically Converts Omega-6 to Omega-3 Fatty Acids in the Body
Shriners Children's Develops New Technology to Prevent Childhood Obesity ST. LOUIS, Oct. 16, 2024 /PRNewswire/ -- According to the Centers for Disease Control, nearly 20% of children and teens are considered obese. Research shows it can have a dramatic impact on a...
Related Services